Piper Jaffray downgraded Mirati Therapeutics (NASDAQ: MRTX) from Overweight to Neutral with a price target of $45.00 (from $50.00).Analyst Charles ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE